
               
               
               7 DRUG INTERACTIONS
               
                  


                  



                     *Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects 

                     **Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects 

                     *** Non-Nucleoside Reverse Transcriptase Inhibitors 
                  
                     Table 7.
                      Effect of Voriconazole on Pharmacokinetics of Other Drugs [see CLINICAL PHARMACOLOGY (12.3)] 
                  


                  


*Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects 
**Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects 
*** Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30 to 100 mg q24h) 
**** Non-Steroidal Anti-Inflammatory Drug 
***** Non-Nucleoside Reverse Transcriptase Inhibitors 
               
               
               
                  
                     
                        
                           
                              •CYP3A4, CYP2C9, and CYP2C19 inhibitors and inducers: Adjust voriconazole  dosage and monitor for adverse reactions  or lack of efficacy (4, 7) 
                           
                              •Voriconazole may increase the concentrations and activity of drugs that are CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce dosage of these other drugs and monitor for adverse reactions (4,7) 
                           
                              • Phenytoin or Efavirenz: with co-administration, increase       maintenance oral and intravenous dosage of  Voriconazole (2.3,7)
                        
                     
                  
               
            
         